Mechanisms of immunotherapy to aeroallergens

Clinical and Experimental Allergy

Volumn 41, Issue 9, 2011, Pages 1235-1246

  Shamji, M H ^a   Durham, S R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; API M 1 PEPTIDE; BEE VENOM; BIRCH POLLEN ALLERGEN; CAT ALLERGEN; CELL PROTEIN; FEL D 1 PEPTIDE; GRASS POLLEN ALLERGEN; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM ALLERGEN; IMMUNOGLOBULIN A2 ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 ANTIBODY; INTERLEUKIN 10; MITE ALLERGEN; PHOSPHOLIPASE A2; PLACEBO; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANTIGEN PRESENTATION; APOPTOSIS; ASTHMA; BASOPHIL; BIRTH POLLEN ALLERGY; CELL CONTACT; CELL INFILTRATION; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOKINE RELEASE; DOMESTIC ANIMAL ALLERGY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EFFECTOR CELL; EOSINOPHIL; GRASS POLLEN ALLERGY; HAY FEVER; HOUSE DUST ALLERGY; HUMAN; HUMORAL IMMUNITY; HYMENOPTERA VENOM ALLERGY; HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; INSECT ALLERGY; LYMPHOCYTE SUBPOPULATION; MAST CELL; NEUTROPHIL; NONHUMAN; NOSE ALLERGY; PEPTIDE IMMUNOTHERAPY; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SKIN ALLERGY; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT RESPONSE;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; BIOLOGICAL MARKERS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; PEPTIDES;

EID: 80051734103     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03804.x     Document Type: Review

References (121)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
2. Lockey RF. "ARIA": global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001; 108:497-99.
3. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87-93.
4. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:319-25.
5. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007: CD001936.
6. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
7. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004; 351:668-74.
8. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-97.
9. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-56.
10. Niggemann B, Jacobsen L, Dreborg S et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006; 61:855-59.
11. Pienkowski MM, Norman PS, Lichtenstein LM. Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol 1985; 76:729-34.
12. Iliopoulos O, Proud D, Adkinson NF Jr et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991; 87:855-66.
13. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; 2:912-15.
14. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51.
15. Nish WA, Charlesworth EN, Davis TL et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994; 93:484-93.
16. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103:468-75.
17. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:1120-25, e2.
18. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005; 60:678-84.
19. Nanda A, O'connor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114:1339-44.
20. Arvidsson MB, Löwhagen O, Rak S. Allergen-specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy 2004; 59:74-80.
21. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-14.
22. Faith A, Richards DF, Verhoef A, Lamb JR, Lee TH, Hawrylowicz CM. Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin Exp Allergy 2003; 33:1209-15.
23. Wachholz PA, Nouri-Aria KT, Wilson DR et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology 2002; 105:56-62.
24. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
25. Durham SR, Ying S, Varney VA et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-65.
26. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2:725-31.
27. Tversky JR, Bieneman AP, Chichester KL, Hamilton RG, Schroeder JT. Subcutaneous allergen immunotherapy restores human dendritic cell innate immune function. Clin Exp Allergy 2010; 40:94-102.
28. Dreschler K, Bratke K, Petermann S et al. Impact of immunotherapy on blood dendritic cells in patients with Hymenoptera venom allergy. J Allergy Clin Immunol 2011; 127:487-94, e1-3.
29. de Heer HJ, Hammad H, Soullie T et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004; 200:89-98.
30. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
31. Ling EM, Smith T, Nguyen XD et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-15.
32. Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010; 184:2194-203.
33. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor b-induced inhibition of T helper type 1 differentiation. J Exp Med 2002; 195:1499-505.
34. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-b inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 2000; 165:4773-477.
35. Karagiannidis C, Akdis M, Holopainen P et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114:1425-33.
36. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-b induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86.
37. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-b induces a regulatory phenotype in CD4+CD25 T cells through Foxp3 induction and down- regulation of Smad7. J Immunol 2004; 172:5149-53.
38. Oida T, Xu L, Weiner HL, Kitani A, Strober W. TGF-β-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol 2006; 177:2331-19.
39. Pilette C, Nouri-Aria KT, Jacobson MR et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-β expression. J Immunol 2007; 178:4658-66.
40. Grindebacke H, Larsson P, Wing K, Rak S, Rudin A. Specific immunotherapy to birch allergen does not enhance suppression of Th2 cells by CD4(+)CD25(+) regulatory T cells during pollen season. J Clin Immunol 2009; 29:752-60.
41. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121:1467-72, 72 e1.
42. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-kit+mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005; 116:73-79.
43. Wilson DR, Irani AM, Walker SM et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705-13.
44. Tsai YG et al. TLR2 agonists enhance CD8+Foxp3+ regulatory T cells and suppress Th2 immune responses during allergen immunotherapy. J Immunol 2010; 184:7229-37.
45. Wilson DR, Nouri-Aria KT, Walker SM et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001; 107:971-76.
46. Van Ree R, Van Leeuwen WA, Dieges PH et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997; 27:68-74.
47. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52:472-82.
48. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982; 70:261-71.
49. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002; 57:423-30.
50. Gehlar K, Schlaak M, Becker W-M, Buffe A. Monitoring allergen Immunotherapy of pollen-allergic patients: The ration of allergen-specificIgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999; 29:497-506.
51. Moverare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol 2001; 86:337-42.
52. Devey ME, Wilson DV, Wheeler AW. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization. Clin Allergy 1976; 6:227-36.
53. Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-208.
54. Garcia BE, Sanz ML, Dieguez I, de las Marinas MD, Oehling A. Modifications in IgG subclasses in the course of immunotherapy with grass pollen. J Investig Allergol Clin Immunol 1993; 3:19-25.
55. Lambin P, Bouzoumou A, Murrieta M et al. Purification of human IgG4 subclass with allergen-specific blocking activity. J Immunol Methods 1993; 165:99-111.
56. Daeron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95:577-85.
57. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11:446-49.
58. Kepley CL, Taghavi S, Mackay G et al. Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem 2004; 279:35139-49.
59. Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clin Exp Allergy 2006; 36:273-82.
60. van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:2944-52.
61. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:915-22.
62. Wurtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008; 38:1290-301.
63. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-59.
64. Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010; 40:1346-52.
65. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
66. James LK, Shamji MH, Walker SM et al. Long-term tolerance following allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127:509-16, e1-5.
67. Punnonen J, Aversa G, de Vries JE. Human pre-B cells differentiate into Ig-secreting plasma cells in the presence of interleukin-4 and activated CD4+ T cells or their membranes. Blood 1993; 82:2781-89.
68. Jabara HH, Loh R, Ramesh N, Vercelli D, Geha RS. Sequential switching from mu to epsilon via gamma 4 in human B cells stimulated with IL-4 and hydrocortisone. J Immunol 1993; 151:4528-33.
69. Agresti A, Vercelli D. Analysis of gamma4 germline transcription in human B cells. Int Arch Allergy Immunol 1999; 118:279-81.
70. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and Toll-like receptors. Allergy 2008; 63:1455-63.
71. Satoguina JS, Weyand E, Larbi J, Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol 2005; 174:4718-26.
72. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126:97-101.
73. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
74. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 12:CD002893.
75. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007; 62:954-57.
76. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-45.
77. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007; 62:958-61.
78. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-18, e2.
79. Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-38, e1-7.
80. Allam JP, Novak N, Fuchs C et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:141-48.
81. Allam JP, Peng WM, Appel T et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368-74, e1.
82. Novak N, Bieber T, Katoh N. Engagement of Fcepsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 2001; 167:797-804.
83. Nieminen K, Laaksonen K, Savolainen J. Three-year follow-up study of allergen- induced in vitro cytokine and signalling lymphocytic activation molecule mRNA responses in peripheral blood mononuclear cells of allergic rhinitis patients undergoing specific immunotherapy. Int Arch Allergy Immunol 2009; 150:370-76.
84. Laaksonen K, Junikka M, Lahesmaa R, Terho EO, Savolainen J. In vitro allergen- induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol 2003; 112:1171-77.
85. Piconi S, Trabattoni D, Rainone V et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. J Immunol 2010; 185:7723-30.
86. von Bubnoff D, Matz H, Frahnert C et al. FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J Immunol 2002; 169:1810-16.
87. Allam JP, Wurtzen PA, Reinartz M et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-β1 and IL-10-producing properties. J Allergy Clin Immunol 2010; 126:638-45, e1.
88. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18:605-17.
89. Passalacqua G, Albano M, Riccio A et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-68.
90. Passalacqua G, Albano M, Fregonese L et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351:629-32.
91. Ippoliti F, De Santis W, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-21.
92. Bahceciler NN, Arikan C, Taylor A et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287-94.
93. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-13.
94. Fanta C, Bohle B, Hirt W et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999; 120:218-24.
95. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-15.
96. Cosmi L, Santarlasci V, Angeli R et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 2006; 36:261-72.
97. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61:1184-90.
98. Savolainen J, Nieminen K, Laaksonen K et al. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007; 62:949-53.
99. Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-41.
100. Dehlink E, Eiwegger T, Gerstmayr M et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36:32-39.
101. Ciprandi G, Fenoglio D, Cirillo I et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005; 95:38-44.
102. Ciprandi G, Cirillo I, Fenoglio D, Marseglia G, Tosca MA. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006; 6:1370-73.
103. Ciprandi G, De Amici M, Tosca MA, Pistorio A, Marseglia GL. Sublingual immunotherapy affects specific antibody and TGF-β serum levels in patients with allergic rhinitis. Int J Immunopathol Pharmacol 2009; 22:1089-96.
104. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408-15.
105. Tonnel AB, Scherpereel A, Douay B et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59:491-97.
106. Andre C, Perrin-Fayolle M, Grosclaude M et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003; 131:111-18.
107. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-09.
108. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009; 124:150-56, e1-5.
109. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53.
110. Scadding G, Durham S. Mechanisms of sublingual immunotherapy. J Asthma 2009; 46:322-34.
111. Varga EM, Francis JN, Zach MS, Klunker S, Aberer W, Durham SR. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009; 39:1353-7.
112. Di Lorenzo G, Mansueto P, Pacor ML et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 123:1103-10, 10e1-4.
113. Eifan AO, Akkoc T, Yildiz A et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010; 40:922-32.
114. Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy 1993; 23:647-60.
115. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4:313-18.
116. Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:2026-36.
117. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117:263-68.
118. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445-55.
119. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005; 2:e78.
120. Campbell JD, Buckland KF, McMillan SJ et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009; 206:1535-47.
121. Larche M. Immunotherapy: Future. Clin Exp Allergy 2011.